Results 11 to 20 of about 21,696 (215)

Necessity to screen and treat latent tuberculosis before ruxolitinib treatment—Ruxolitinib-associated disseminated tuberculosis: A case report and literature review

IDCases, 2020
Ruxolitinib, a Janus kinase inhibitor, considerably improves symptoms of patients with polycythemia vera and primary or secondary myelofibrosis. However, its association with the development of infectious complications is a concern. Herein, we report the
Kei Kasahara, Naokuni Hishiya, Yuki Suzuki   +2 more
exaly   +4 more sources

Comparative Analysis of Myelofibrosis Treatment Outcomes with the Use of Ruxolitinib Versus Ruxolitinib with Subsequent Allogeneic Hematopoietic Stem Cell Transplantation [PDF]

Клиническая онкогематология, 2021
Aim. To comparatively analyze myelofibrosis treatment outcomes with the use of ruxolitinib versus ruxolitinib with subsequent allogeneic hematopoietic stem cell transplantation (allo-HSCT) as well as to assess the efficacy of ruxolitinib in pre- and post-
Mariya Vladimirovna Barabanshchikova, E. V. Morozova, Yu. Yu. Vlasova, T. L. Gindina, A. V. Evdokimov, I. M. Barkhatov, V. V. Baikov, I. O. Ivanova, T. A. Rudakova, E. A. Bakin, I. S. Moiseev, A. D. Kulagin   +11 more
doaj   +2 more sources

c-Src binds to the cancer drug Ruxolitinib with an active conformation. [PDF]

PLoS ONE, 2014
The cancer drug Ruxolitinib is a potent janus kinase inhibitor approved for the treatment of the myeloproliferative neoplasms. In addition, Ruxolitinib has weak inhibitory activity against a panel of other kinases, including Src kinase.
Yankun Duan, Lin Chen, Yongheng Chen, Xue-gong Fan   +3 more
doaj   +2 more sources

Ruxolitinib stopped before transplantation does not induce cytokine release in myelofibrosis

Cancer Immunology, Immunotherapy
Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by marrow fibrosis, splenomegaly, constitutional symptoms and cytopenia with a proinflammatory and profibrotic cytokine phenotype involving the JAK-STAT pathway.
Sara Villar, Emmanuel Curis, Marie-Hélène Schlageter, Nelly Bosselut, Amandine Charbonnier, Marie-Thérèse Rubio, Pascal Turlure, Hélène Labussière, Jacques-Olivier Bay, Jérome Cornillon, Laure Vincent, Corentin Orvain, Jean-Jacques Kiladjian, David Michonneau, Gérard Socié, Marie Robin   +15 more
doaj   +2 more sources

Secondary Pulmonary Alveolar Proteinosis Associated With Ruxolitinib After Bone‐Marrow Transplantation: A Case With Transient Improvement Following Drug Discontinuation [PDF]

Respirology Case Reports
Ruxolitinib is a Janus kinase (JAK) 1/2 inhibitor used to treat steroid‐refractory graft‐versus‐host disease, wherein pulmonary alveolar proteinosis (PAP) is a rare complication.
Taiki Yanagi, Maki Asami‐Noyama, Kaoru Yamamoto, Yoshinobu Hoshii, Yasushi Ichiyama, Masatoshi Okimura, Tetsuya Fujii, Junki Suizu, Misa Harada, Keita Murakawa, Kazuki Hamada, Toshiaki Utsunomiya, Yoriyuki Murata, Keiji Oishi, Nobutaka Edakuni, Tomoyuki Kakugawa, Tsunahiko Hirano, Kazuto Matsunaga   +17 more
doaj   +2 more sources

A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera [PDF]

, 2023
Introduction:Ruxolitinib is a small -molecule inhibitor of the JAK1/2 pathway. This study aimed to reveal the results and side-effect profile of the use of ruxolitinib as a treatment option in polycythemia vera (PV).Methods:A total of 34 patients with PV
Serdal Korkmaz, Fadime Ersoy Dursun, Mehmet Hilmi Doğu, Gulsum Akgun Cagliyan, Albayrak, Murat, Anıl Tombak, Altuntaş, Fevzi, Baştürk, Abdulkadir, Dal, Mehmet Sinan, İsmet Aydoğdu, Sibel Kabukçu Hacıoğlu, METIN BAGCI, Gülsüm Akgün Çağlıyan, Mehmet Ali Erkurt, Mehmet Sinan Dal, Tombak, Anıl, Serin, İstemi, Aydoğdu, İsmet, ANIL TOMBAK, Merih Reis Aras, Turgut, Burhan, Abdulkadir Baştürk, Burhan Turgut, Merter, Murat, Dursun, Fadime, Turgay Ulaş, Ulaş, Turgut, Sibel Hacioglu, Akgün Çağlıyan, Gülsüm, Erkurt, Mehmet Ali, Fevzi Altuntaş, Doğu, Mehmet Hilmi, Korkmaz, Serdal, Metin Bağcı, Ekinci, Ömer, Aras, Merih Reis, Mustafa Merter, İstemi Serin, Hacıoğlu, Sibel, Murat Albayrak, Sinan Demircioğlu, Ömer Ekinci, Bağcı, Metin, Demircioğlu, Sinan   +43 more
core   +1 more source

Salvage Therapy With Low-Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem Cell Transplantation

Frontiers in Pharmacology, 2021
Bronchiolitis obliterans syndrome (BOS) is a life-threatening pulmonary manifestation of chronic graft versus host disease (cGVHD) post-allogeneic hematopoietic stem cell transplantation (HSCT), without clear standard of care.
Yanmin Zhao, Yanmin Zhao, Guifang OuYang, Jimin Shi, Jimin Shi, Yi Luo, Yi Luo, Yamin Tan, Yamin Tan, Jian Yu, Jian Yu, Huarui Fu, Huarui Fu, Xiaoyu Lai, Xiaoyu Lai, Lizhen Liu, Lizhen Liu, He Huang, He Huang   +18 more
doaj   +1 more source

Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms

Blood Cancer Journal, 2023
The Janus kinase 2 (JAK2)-driven myeloproliferative neoplasms (MPNs) are chronic malignancies associated with high-risk complications and suboptimal responses to JAK inhibitors such as ruxolitinib.
Charly Courdy, Loïc Platteeuw, Charlotte Ducau, Isabelle De Araujo, Emeline Boet, Ambrine Sahal, Estelle Saland, Valérie Edmond, Suzanne Tavitian, Sarah Bertoli, Pierre Cougoul, Fanny Granat, Laura Poillet, Caroline Marty, Isabelle Plo, Jean-Emmanuel Sarry, Stéphane Manenti, Véronique Mansat-De Mas, Carine Joffre   +18 more
doaj   +1 more source

Exploring redox vulnerabilities in JAK2V617F-positive cellular models

Hematology, Transfusion and Cell Therapy, 2021
Background: In Philadelphia chromosome-negative myeloproliferative neoplasm (MPN) models, reactive oxygen species (ROS) are elevated and have been implicated in genomic instability, JAK2/STAT signaling amplification, and disease progression. Although the
Keli Lima, Lucia Rossetti Lopes, João Agostinho Machado-Neto   +2 more
doaj   +1 more source

Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review [PDF]

, 2023
BACKGROUND AND OBJECTIVE: Ruxolitinib is a tyrosine kinase inhibitor targeting the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways.
Munnink, T H Oude, Touw, D J, Touw, D J; id_orcid, Morsink, L M, Lub-de Hooge, M N, Munnink, T H Oude; id_orcid, Morsink, L M; id_orcid, Lub-de Hooge, M N; id_orcid, Appeldoorn, T Y J   +8 more
core   +2 more sources